Achieve Life Sciences (STU:SP4P) Long-Term Debt: €8.06 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SP4P Achieve Life Sciences Inc STU:SP4P
39 GF Score
Price €5.50
! 4 Warning Signs
View Full Analysis

What is Achieve Life Sciences Long-Term Debt?

Achieve Life Sciences STU:SP4P +0.92% 39 Long-Term Debt is €8.06 Mil as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 39/100. The stock has 4 warning signs investors should review.

Achieve Life Sciences's Long-Term Debt for the quarter that ended in Mar. 2026 was €8.06 Mil.

Achieve Life Sciences's quarterly Long-Term Debt increased from Sep. 2025 (€7.39 Mil) to Dec. 2025 (€9.55 Mil) but then declined from Dec. 2025 (€9.55 Mil) to Mar. 2026 (€8.06 Mil).

Achieve Life Sciences's annual Long-Term Debt increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€9.39 Mil) and increased from Dec. 2024 (€9.39 Mil) to Dec. 2025 (€9.55 Mil).

Achieve Life Sciences  (STU:SP4P) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Achieve Life Sciences Long-Term Debt Related Terms

Achieve Life Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences Long-Term Debt Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.20 0.00 0.00 9.39 9.55

Achieve Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.01 7.51 7.39 9.55 8.06
STU:SP4P
39GF Score
Achieve Life Sciences Inc STU:SP4P
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €8.06 Mil mean?
Achieve Life Sciences (STU:SP4P) has a Long-Term Debt of €8.06 Mil as of Mar. 2026.
Is Achieve Life Sciences' Long-Term Debt too high?
Achieve Life Sciences' current Long-Term Debt is €8.06 Mil. Overall, Achieve Life Sciences has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' Long-Term Debt compare to STTK and CRMD?
Achieve Life Sciences' Long-Term Debt of €8.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Achieve Life Sciences's current Long-Term Debt is €8.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current Long-Term Debt of €8.06 Mil. The current Long-Term Debt is €8.06 Mil. Achieve Life Sciences' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current Long-Term Debt is €8.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
39GF Score

Get the complete analysis for STU:SP4P

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.50
Price